Status:
COMPLETED
Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
18+ years
Brief Summary
The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohor...
Eligibility Criteria
Inclusion
- Older than 18 years
- Diagnosis of non-valvular AF (ICD code 427.31)
- Pharmacological treatment with VKAs or rivaroxaban following diagnosis
Exclusion
- \-
Key Trial Info
Start Date :
June 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
249 Patients enrolled
Trial Details
Trial ID
NCT03462446
Start Date
June 1 2015
End Date
May 1 2016
Last Update
March 12 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Granada, Spain